Further to the announcement regarding the proposed acquisition of BTG plc (LON: BTG) by Bidco, to be implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 released on 20 November 2018, BTG and Boston Scientific are pleased to confirm that the Transaction has received merger control clearance from the US Federal Trade Commission under the HSR Act, on 25 July 2019 the CNMC issued a clearance decision under the Spanish Competition Act and on 2 August 2019, the Federal Competition Authority of Austria issued a clearance decision pursuant to Sec 11 Para 4 Austrian Cartel Act.
The Scheme remains subject to the satisfaction or (if capable of waiver) waiver of the remaining Conditions set out in the Scheme Document, including the Court’s sanction of the Scheme at the Court Hearing and the delivery of an office copy of the Court Order to the Registrar of Companies. The Court Hearing is expected to take place on 15 August 2019 and the Scheme is expected to become Effective on 19 August 2019.
BTG is applying to the FCA and to the London Stock Exchange for: (a) the listing of BTG Shares on the premium listing segment of the Official List and the trading of BTG Shares on the Main Market, to be suspended with effect from 7.30 a.m. (London time) on 19 August 2019; and (b) such listing and admission to trading of BTG Shares to be cancelled with effect from 8.00 a.m. on 20 August 2019. Such suspension and cancellation of listing and admission to trading is subject to the Court Hearing not being adjourned, and to the Scheme becoming effective, respectively.
If any of the expected times and/or dates above change, the revised times and/or dates will be notified to BTG Shareholders by announcement through a Regulatory Information Service. Such announcement will, subject to certain restrictions relating to persons resident in Restricted Jurisdictions, also be available on BTG’s website.
